Back
The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
I - Interstitial/parenchymal lung disease
I.a
Pneumonitis (ILD)
I.b
Pneumonitis (ILD), acute and/or severe (may cause ARDS)
I.e
Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.g
Pulmonary fibrosis
I.m
Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
I.o
Pulmonary alveolar proteinosis (PAP)
I.w
Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence
II - Pulmonary edema - Acute lung injury - ARDS
VII - Pulmonary vasculopathy
XVI - Imaging
XVIII - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX - Pathology
XIX.a
Path: NSIP-cellular pattern (see also Ia, Ib)
XIX.d
Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XIX.e
Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)
XIX.n
Path: Pulmonary alveolar proteinosis pattern (PAP pattern)
XIX.o
Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XIX.q
Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign)
XIX.v
Path: NSIP-fibrotic pattern
XIX.cy
Path: Opportunistic pulmonary infection (see also XVII/XVIIb-d-e)